{"DataElement":{"publicId":"3623447","version":"1","preferredName":"Tumor Infiltrating Lymphocyte Level Category","preferredDefinition":"Text term to describe the extent of lymphocyte infiltration into tumor.","longName":"2678227v1.0:3623441v1.0","context":"BOLD","contextVersion":"1","DataElementConcept":{"publicId":"2678227","version":"1","preferredName":"Pathology Tumor Infiltrating Lymphocyte Level","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.:A position on a scale measuring intensity, quality, or amount.","longName":"2437801v1.0:2678009v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2437801","version":"1","preferredName":"Pathology","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","longName":"C18189","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathology","conceptCode":"C18189","definition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07F9D71F-CC64-6C7F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-15","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-12-15","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2678009","version":"1","preferredName":"Tumor Infiltrating Lymphocyte Level","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.:A position on a scale measuring intensity, quality, or amount.","longName":"C12546:C25554","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Level","conceptCode":"C25554","definition":"A position on a scale measuring intensity, quality, or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978A68F-3FFE-290F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"ONEDATA","dateModified":"2007-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978CB55-ECB8-5636-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"11/14/2010 released DEC per direction of model owner as part of caDSR model cleanup activity.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3623441","version":"1","preferredName":"Tumor Infiltrating Lymphocyte Category","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer._Category; used informally to mean a class of things.","longName":"3623441v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown/not reported","valueDescription":"Not Stated Unknown","ValueMeaning":{"publicId":"3371381","version":"1","preferredName":"Not Stated Unknown","longName":"3371381","preferredDefinition":"Not provided or available.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B85BD33E-6B5D-07C2-E040-BB89AD430D59","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCB9CF63-FFDE-864D-E040-BB89AD434A34","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","deletedIndicator":"No"},{"value":"Extensive","valueDescription":"Extensive Tumor Infiltrating Lymphocyte","ValueMeaning":{"publicId":"3623442","version":"1","preferredName":"Extensive Tumor Infiltrating Lymphocyte","longName":"3623442","preferredDefinition":"Large in quantity, range, or spatial extent.: Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extensive","conceptCode":"C47863","definition":"Large in quantity, range, or spatial extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF63-FFEC-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCB9CF64-0005-864D-E040-BB89AD434A34","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","deletedIndicator":"No"},{"value":"Present","valueDescription":"Present Tumor Infiltrating Lymphocyte","ValueMeaning":{"publicId":"3623443","version":"1","preferredName":"Present Tumor Infiltrating Lymphocyte","longName":"3623443","preferredDefinition":"Being or existing in a specified place or at the specified time.: Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF64-0012-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCB9CF64-002B-864D-E040-BB89AD434A34","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","deletedIndicator":"No"},{"value":"None/minimal","valueDescription":"None To Minimum Tumor Infiltrating Lymphocyte","ValueMeaning":{"publicId":"3623444","version":"1","preferredName":"None To Minimum Tumor Infiltrating Lymphocyte","longName":"3623444","preferredDefinition":"No person or thing, nobody, not any.: Used as a function word to indicate direction, purpose, or movement.: The smallest possible quantity.: Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Minimum","conceptCode":"C25570","definition":"The smallest possible quantity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF64-003A-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCB9CF64-0053-864D-E040-BB89AD434A34","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3623440","version":"1","preferredName":"Tumor Infiltrating Lymphocyte Category","preferredDefinition":"Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.:Category; used informally to mean a class of things.","longName":"C12546:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Infiltrating Lymphocyte","conceptCode":"C12546","definition":"Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF63-FFAE-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF63-FFBF-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"REEVESD","dateModified":"2012-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3461586","version":"1","longName":"BOLD:Breast Oncology Local Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461587","version":"1","longName":"Preoperative Elements","context":"NCIP"},{"publicId":"3461588","version":"1","longName":"General Elements","context":"NCIP"}]},{"publicId":"3886753","version":"1","longName":"General Elements","context":"BOLD","ClassificationSchemeItems":[{"publicId":"3902138","version":"1","longName":"General","context":"BOLD"}]},{"publicId":"3886755","version":"1","longName":"Preoperative Elements","context":"BOLD","ClassificationSchemeItems":[{"publicId":"3902140","version":"1","longName":"Preoperative","context":"BOLD"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tumor infiltrating lymphocyte","type":"Preferred Question Text","description":"Tumor infiltrating lymphocytes:","url":null,"context":"NCIP"}],"origin":"BOLD:Breast Oncology Local Disease Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CCB9CF64-005D-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-23","modifiedBy":"REEVESD","dateModified":"2016-09-06","changeDescription":"Curated to support Breast Oncology Local Disease (BOLD) Initiative","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}